Skip Navigation

European Journal of Heart Failure 2001 3(5):517-526; doi:10.1016/S1388-9842(01)00156-8
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (51)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Adamopoulos, S.
Right arrow Articles by Kremastinos, D. Th.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamopoulos, S.
Right arrow Articles by Kremastinos, D. Th.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

A glossary of circulating cytokines in chronic heart failure

Stamatis Adamopoulos*, John T. Parissis and Dimitrios Th. Kremastinos

Second Department of Cardiovascular Medicine, Onassis Cardiac Surgery Center Athens, Greece

* Corresponding author. Zinonos 9, Halandri, 15234, Athens, Greece. Tel.: +30-16848463; fax: +30-19493373. E-mail address: elbee{at}ath.forthnet.gr (S. Adamopoulos)


   Abstract

Recent studies have emphasized the importance of biologically active molecules, termed cytokines, in the development and progression of the syndrome of chronic heart failure. This article summarizes a glossary of major cytokines and other cytokine-related inflammatory factors implicated in the pathophysiology of chronic heart failure, describing the source of their synthesis and factors regulating their secretion and analyzing their biologic effects on the cardiovascular system.

Key Words: Chronic heart failure • Cytokines • Inflammatory factors • Immune activation

Received December 14, 2000; Revised April 11, 2001; Accepted April 26, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
J. T. Parissis, D. Farmakis, M. Nikolaou, D. Birmpa, V. Bistola, I. Paraskevaidis, I. Ikonomidis, S. Gaitani, K. Venetsanou, G. Filippatos, et al.
Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study
Eur J Heart Fail, October 1, 2009; 11(10): 967 - 972.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. T. Parissis, M. Nikolaou, D. Farmakis, I. A. Paraskevaidis, V. Bistola, K. Venetsanou, D. Katsaras, G. Filippatos, and D. T. Kremastinos
Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure
Eur J Heart Fail, February 1, 2009; 11(2): 163 - 169.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Trikas, C. Antoniades, G. Latsios, K. Vasiliadou, I. Karamitros, D. Tousoulis, C. Tentolouris, and C. Stefanadis
Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure
Eur J Heart Fail, December 1, 2006; 8(8): 804 - 809.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J T Parissis, S Adamopoulos, D Farmakis, G Filippatos, I Paraskevaidis, F Panou, E Iliodromitis, and D Th Kremastinos
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure
Heart, December 1, 2006; 92(12): 1768 - 1772.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. Rubaj, P. Rucinski, K. Rejdak, K. Oleszczak, D. Duma, P. Grieb, and A. Kutarski
Biventricular versus right ventricular pacing decreases immune activation and augments nitric oxide production in patients with chronic heart failure
Eur J Heart Fail, October 1, 2006; 8(6): 615 - 620.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
F. Kosar, Y. Aksoy, G. Ozguntekin, I. Ozerol, and E. Varol
Relationship between cytokines and tumour markers in patients with chronic heart failure
Eur J Heart Fail, May 1, 2006; 8(3): 270 - 274.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. F. M. Segers, I. Van Riet, L. J. Andries, K. Lemmens, M. J. Demolder, A. J. M. L. De Becker, M. M. Kockx, and G. W. De Keulenaer
Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms
Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1370 - H1377.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. Tousoulis, C. Antoniades, C. Vassiliadou, M. Toutouza, C. Pitsavos, C. Tentolouris, A. Trikas, and C. Stefanadis
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure
Eur J Heart Fail, December 1, 2005; 7(7): 1126 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine
Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. J. Toth, D. E. Matthews, P. A. Ades, M. D. Tischler, P. Van Buren, M. Previs, and M. M. LeWinter
Skeletal muscle myofibrillar protein metabolism in heart failure: relationship to immune activation and functional capacity
Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E685 - E692.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. A. Jortani, S. D. Prabhu, and R. Valdes Jr
Strategies for Developing Biomarkers of Heart Failure
Clin. Chem., February 1, 2004; 50(2): 265 - 278.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Adamopoulos, J. T. Parissis, I. Paraskevaidis, D. Karatzas, E. Livanis, M. Georgiadis, G. Karavolias, D. Mitropoulos, D. Degiannis, and D. Th. Kremastinos
Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy
Eur. Heart J., December 2, 2003; 24(24): 2186 - 2196.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Persinger, Y. Janssen-Heininger, S. S. Wing, D. E. Matthews, M. M. LeWinter, and M. J. Toth
Effect of heart failure on the regulation of skeletal muscle protein synthesis, breakdown, and apoptosis
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1001 - E1008.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P A Henriksen and D E Newby
Therapeutic inhibition of tumour necrosis factor {alpha} in patients with heart failure: cooling an inflamed heart
Heart, January 1, 2003; 89(1): 14 - 18.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A.P. Coletta, N. Nikitin, A.L. Clark, and J.G.F. Cleland
Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure
Eur J Heart Fail, January 1, 2003; 5(1): 95 - 99.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
A.P. Coletta, A.L. Clark, P. Banarjee, and J.G.F. Cleland
Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH
Eur J Heart Fail, August 1, 2002; 4(4): 559 - 561.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.